FDA Announces Intent to Tighten Screws on GLP-1 Drug Compounding What is happening: On February 6, 2026, FDA issued a public statement indicating that it plans to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies
Ozempic, Wegovy Users Want NJ To Host Vision-Loss Suits
Berobenatide had a favorable risk-benefit profile with very few adverse events despite the fact that dose deescalation was not allowed in the study. The safety profile of berobenatide in VESPER-2 was consistent with the GLP-1 RA class, and no new safety signals were identified
FIGURE 6 Collectively, these data provide compelling evidence that GO@GSH-FA effectively mitigates the inflammatory response induced by OGD/R, as indicated by the marked reduction in the expression of key proinflammatory markers
Or what if the side effects, cost, or long-term dependence just dont feel right
Cross-contamination between peptide vials is the most common cause of unexplained potency loss in multi-peptide protocols
